Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Insulin Delivery

BD CY Q4 '18 (FY Q1 '19) Earnings Update

Here is a brief preview of this blast: BD held their Q4 '18 earnings call and provided a brief update on their diabetes business unit. Senior management disclosed they have filed their T2DM patch pump in the US and European and anticipate a launch in late 2019. When asked by an analyst about their market approach for the T2DM patch pump, senior management commented that BD is in the process of defining their channel strategy. Furthermore, management does not anticipate any new clinical data to presented at ADA 2019.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.